Stock data
| Market cap. | £53.9m |
| Last close | 39.00p |
| High / Low (52 weeks) | 44.0p / 25.2p |
| Stock market listing | AIM |
| Forecast net cash (£m) | 12.5 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 20 | 34.48 | 6.85 |
| Relative * | 25.89 | 45.53 | 17.42 |
* % Relative to local index
Other companies covered in sector
| Y/E Jan | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 0.0 | (2.1) | (2.3) | (3.0) | N/A | N/A |
| 2011A | 0.0 | (2.5) | (2.7) | (3.5) | N/A | N/A |
| 2012E | 0.0 | (4.3) | (4.1) | (2.7) | N/A | N/A |
| 2013E | 0.0 | (6.2) | (6.1) | (4.0) | N/A | N/A |
Last updated on 19/04/2012
Latest research
On the cusp of the clinic
Update | Pharmaceutical & Healthcare | 30/03/2012
Busy behind the scenes
Update | Pharmaceutical & Healthcare | 28/10/2011
A new wave of discovery
Review | Pharmaceutical & Healthcare | 01/08/2011
A pioneering paradigm
Outlook | Pharmaceutical & Healthcare | 09/05/2011
Funding secured
QuickView | Pharmaceutical & Healthcare | 16/02/2011
Investment summary
Protocols for two Phase I trials of e-Therapeutics' cancer candidate, ETS2101, in brain cancers (US) and in solid tumours (UK) have been approved by the regulators. Enrolment is imminent, and first data is expected by end-2012. Discussions with regulators and specialist CROs are on track to enable the three other core R&D assets to start new clinical trials this year. In addition to its core pipeline, e-Therapeutics has a proprietary network pharmacology discovery platform. End-July cash of £15.3m provides funds through 2013 to exploit its platform fully and build a broader in-house pipeline of NCEs and repositioned drugs.
Last updated on 23/04/2012
Industry outlook
Network pharmacology could potentially revolutionise drug discovery and, in the process, shorten the path to market by minimising technical risks (failure on safety or efficacy grounds) and drug development costs. e-Therapeutics is well positioned with limited direct competition and growing industry acceptance of, and interest in, systems biology-based multi-target approaches to drug discovery.
Last updated on 23/04/2012
Key management
| Oliver Francis Wintour James, Chairman |
| Malcolm Young, CEO |
| Daniel Elger , CFO |
Company address
| Holland Park Holland Drive Newcastle Upon Tyne NE2 4LZ United Kingdom View website |
